The capital structure appears increasingly fragile, with a current ratio of 0.50 and a substantial $71.1 million goodwill concentration relative to $35.3 million in total equity.
| Total Current Assets | 29.42M | 27.54M | 10.97M | 7.73M | 2.69M |
| Cash & Short-Term Investments | 2.63M | 3.92M | 112 | 0 | 0 |
| Cash Only | 2.63M | 3.92M | 112 | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.08M | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 83.39 | - | - | - | - |
| Inventory | 22.66M | 22.29M | 8.27M | 0 | 0 |
| Days Inventory Outstanding | 6.92K | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 71.28M | 73.4M | 73.4M | 40M | 40M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 71.11M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 169.25K | 73.4M | 73.4M | 40M | 40M |
| Total Assets | 100.7M | 100.94M | 84.37M | 47.73M | 42.69M |
| Asset Turnover | 0.06x | - | - | - | - |
| Asset Growth % | 134.71% | 19.64% | 76.74% | 11.82% | - |
| Total Current Liabilities | 58.81M | 49.49M | 32.7M | 21.05M | 5.85M |
| Accounts Payable | 8.88M | 13.23M | 3.71M | 1.29M | 92.31K |
| Days Payables Outstanding | 3.37K | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.87M | 22.65M | 28.4M | 0 | 0 |
| Current Ratio | 0.50x | 0.56x | 0.34x | 0.37x | 0.46x |
| Quick Ratio | 0.12x | 0.11x | 0.08x | 0.37x | 0.46x |
| Cash Conversion Cycle | 3.64K | - | - | - | - |
| Total Non-Current Liabilities | 6.62M | 6.59M | 5.53M | 1.15M | 576K |
| Long-Term Debt | 3.8M | 3.8M | 3.8M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 2.82M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 2.78M | 1.73M | 1.15M | 576K |
| Total Liabilities | 65.43M | 56.08M | 38.23M | 22.2M | 6.42M |
| Total Debt | 3.8M | 3.8M | 3.8M | 0 | 0 |
| Net Debt | 1.17M | -124.8K | 3.8M | 0 | 0 |
| Debt / Equity | 0.11x | 0.08x | 0.08x | - | - |
| Debt / EBITDA | -0.09x | - | - | - | - |
| Net Debt / EBITDA | -0.03x | - | - | - | - |
| Interest Coverage | -146.37x | -107.72x | - | - | - |
| Total Equity | 35.27M | 44.87M | 46.14M | 25.54M | 36.27M |
| Equity Growth % | 127.89% | -2.76% | 80.69% | -29.59% | - |
| Book Value per Share | 0.35 | 0.61 | 0.64 | 0.29 | 0.40 |
| Total Shareholders' Equity | 35.27M | 44.87M | 46.14M | 25.54M | 36.27M |
| Common Stock | 9.3K | 8.35K | 7.16K | 6.75K | 6.75K |
| Retained Earnings | -96.18M | -64.04M | -39.28M | -18.13M | -5.43M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity shortfall
As reported in recent financial statements, CTOR's equity base has experienced significant volatility, declining from $58.4 million in 2026Q1 to $35.3 million by 2026Q2, reflecting the rapid erosion of shareholder value as the company funds its commercial launch through persistent operational losses.
The downward trend in equity, coupled with a widening deficit in retained earnings, suggests that the company is consuming its capital base at an unsustainable rate. Investors should monitor whether this trajectory necessitates further dilutive equity issuance to maintain basic operational continuity.
Based on the company's 2026Q2 balance sheet, the current ratio stands at a precarious 0.50, indicating that current liabilities significantly outweigh liquid assets, leaving the firm with minimal buffer to manage its ongoing commercialization expenses and short-term obligations.
The sharp decline in cash from $7.3 million in 2026Q1 to $2.6 million in 2026Q2 highlights an acute liquidity risk. This suggests that the company may lack the necessary financial flexibility to navigate unexpected operational hurdles without immediate external capital support.
According to the 2026Q2 balance sheet, goodwill accounts for $71.1 million of the $100.7 million in total assets, representing a substantial portion of the company's valuation that is tied to intangible value rather than tangible productive capacity.
The heavy reliance on goodwill suggests that the asset base is highly sensitive to impairment risks if the commercial performance of LYMPHIR fails to meet initial expectations. This asset structure warrants further investigation into the underlying valuation assumptions supporting these intangible holdings.
As indicated by the 2026Q2 financial data, the presence of $3.8 million in debt alongside a negative retained earnings balance of $96.2 million underscores a capital structure that is heavily reliant on external financing to offset chronic operational deficits.
The lack of tangible assets, such as PPE, implies that the company is entirely dependent on its intellectual property and commercial execution to generate value. This creates a binary risk profile where the balance sheet provides little protection in the event of a commercial launch failure.
Quick answers to the most common questions about buying CTOR stock.
As of 2025, Citius Oncology, Inc. (CTOR) had total assets of $100.9M including $27.5M in current assets.
Citius Oncology, Inc. (CTOR) carries total debt of $3.8M, offset by $3.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Citius Oncology, Inc. (CTOR) has total shareholders' equity (book value) of $44.9M ($0.61 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Citius Oncology, Inc. (CTOR) reported a current ratio of 0.56x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.